

WHY DOES DBS DO THE SAME THING IN THE STN AND GPI?

Michael Chary, PhD and Brian Kopell, MD
Mount Sinai Hospital, Department of Neurosurgery



Overview

DBS in Parkinson's

In the basal ganglia, deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal segment of the globus pallidus (GPi) is thought to alleviate the akinesia and rigidity of Parkinson's disease by removing the pathological inhibition of the thalamus by GPi. Disinhibiting the thalamus should restore thalamocortical activity.

Target inhibition vs. efferent activation

How electrical stimulation leads to inhibition is unclear, as is whether inhibition of nerve tissue near the electrode is the main therapeutic mechanism of DBS. Here we show a computational model demonstrating how DBS of the STN and GPi induce different patterns of brain activity. These differences may explain the increased incidence of adverse effects in STN stimulation, increased medication reductions with STN stimulation, and preference of GPi stimulation for dystonia.






Figure 1: Simplified model of basal ganglia.

Results


Stimulating STN and GPi induce different patterns of network activity




STN and GPi are part of the same eigenvector



Stimulation of STN and GPi activate the second eigenvector similarly



Methods



Simulate activity

$$\mathbf{v} = \mathbf{M} \cdot \mathbf{v} + \mathbf{I}$$
$$P[I_i] = \frac{1}{1 + e^{-I_i}}$$

Update rule
Stochastic update

Identify functional pathways

$$\mathbf{M} \cdot \mathbf{e}_i = \lambda_i \mathbf{e}_i$$

Each eigenvector is a functional pathway.

Represent relative contributions

Compare $\mathbf{I}_{\text{STN}} \cdot \mathbf{e}_i$ and $\mathbf{I}_{\text{GPi}} \cdot \mathbf{e}_i$

Conclusions

1. STN and GPi stimulation (i) activate the same functional pathway (eigenvector) similarly (ii) inhibit their immediate target and (iii) require activation of adjacent white matter afferents to alter thalamocortical activity.
2. STN stimulation increases activity throughout the basal ganglia more than GPi stimulation with the same pattern—may explain why STN stimulation reduces the amount of antiparkinsonian medication needed but also is associated with more adverse effects.
3. Stimulation of GPi but not STN decreases firing rates in GPe —may explain why GPi stimulation is more favored in dystonias.